Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gloucester Pharma Snags $29 Million Series D

This article was originally published in The Pink Sheet Daily

Executive Summary

As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.

You may also be interested in...



Celgene Pays $340 Million For Gloucester And Its New Drug

Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.

Celgene Pays $340 Million For Gloucester And Its New Drug

Celgene already sells several hematological cancer meds, so the deal shouldn't require new marketing infrastructure.

Gloucester's Istodax Gains FDA Approval Ahead Of New Regulatory Requirements

With FDA's approval a week ahead of the PDUFA date, Gloucester Pharmaceuticals will bring its first product to market, the second HDAC inhibitor approved in cancer.

Related Content

Topics

UsernamePublicRestriction

Register

PS069887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel